• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Leading Alzheimer’s Theory Called Into Question As Another Drug Fails Trials

November 17, 2023 by Deborah Bloomfield

Two phase 3 trials of an Alzheimer’s drug have failed to demonstrate significant improvements in cognitive function, throwing doubt on one of the leading theories as to the cause of the neurodegenerative disease.

The so-called “amyloid hypothesis” proposes that build-up of a protein called amyloid-beta is responsible for the neuronal death and degeneration that is characteristic of Alzheimer’s disease. More than a century ago, plaques of an unknown protein were discovered in the brain of someone who died with dementia. In 1984, the amyloid-beta protein was discovered and still to this day remains one of the key suspects in Alzheimer’s pathogenesis.

Advertisement

However, as these plaques are also present in the brains of many elderly people with normal cognition, and because the development of treatments had failed for many years to get off the ground, some have called into question the hypothesis’s validity. There were even claims of fabrication of evidence in a highly cited paper that supported the theory last year. And the two most recent trials don’t appear to lend credence to it either.

The trials, both of which involved almost 1,000 people, tested a drug called gantenerumab in people with early Alzheimer’s disease. While the monoclonal antibody treatment did lead to a lower amyloid plaque burden compared to a placebo, there was no sign of the improved cognitive function that you might expect to accompany this.

This is “surprising”, writes Lon Schneider in an accompanying editorial. Gantenerumab is similar to two other drugs, aducanumab and lecanemab, which have both been approved by the Food and Drug Administration (FDA) for the treatment of early Alzheimer’s disease, Schneider explains. All three drugs contain synthetic antibodies that bind to amyloid-beta in the brain to help reduce plaques, although whether this translates to improvements in dementia symptoms is debated, especially in light of the latest findings.

Participants were randomly assigned to receive either gantenerumab or a placebo once a fortnight for 116 weeks. To assess their dementia severity before and after the trials, the researchers used the Clinical Dementia Rating scale–Sum of Boxes (CDR-SB) – giving each a score between zero and 18, with higher scores indicating greater cognitive impairment.

Advertisement

After more than two years, there was no significant difference between the changes in CDR-SB scores of those on the drug or the placebo, demonstrating that in neither trial did gantenerumab significantly improve cognition.

“The gantenerumab trials add to the evidence of variable, small clinical effects of antiamyloid antibodies. Depending on one’s perspective, the results of the antibody trials to date either reinforce confidence in this therapeutic approach and its clinical meaningfulness or support a view that the effects are small, unreliable, and barely distinguishable from no effect,” concludes Schneider.

However, Schneider also notes some shortcomings of the trials, including risk of bias and inadequate masking of the drug and placebo, and suggests they may not have been long enough to see a real difference in Alzheimer’s symptoms.

“If a meaningful effect is not apparent after 1.5 to 2 years of treatment, there may be hope that it manifests in the future.”

Advertisement

After decades of research into the role of amyloid plaques in Alzheimer’s pathogenesis, it seems we’ll still have to wait to get a definitive answer.

“There is much we do not know about targeting amyloids in patients with Alzheimer’s disease, and perhaps we will learn more from ongoing prevention or registry trials of antiamyloid antibodies in clinical practice,” says Schneider.

The results of the trials are published in The New England Journal of Medicine.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Turkey mutually parts ways with head coach Senol Gunes
  2. China Evergrande shares slide 6% in early trade
  3. French watchdog chief calls for ban on ‘payment for order flow’ in EU stock market
  4. IFLScience The Big Questions: How Is Climate Change Affecting Polar Bear Populations?

Source Link: Leading Alzheimer's Theory Called Into Question As Another Drug Fails Trials

Filed Under: News

Primary Sidebar

  • What Did Neanderthals Sound Like?
  • One Star System Could Soon Dazzle Us Twice With Nova And Supernova Explosions
  • Unethical Experiments: When Scientists Really Should Have Stopped What They Were Doing Immediately
  • The First Humans Were Hunted By Leopards And Weren’t The Apex Predators We Thought They Were
  • Earth’s Passage Through The Galaxy Might Be Written In Its Rocks
  • What Is An Einstein Cross – And Why Is The Latest One Such A Unique Find?
  • If We Found Life On Mars, What Would That Mean For The Fermi Paradox And The Great Filter?
  • The Longest Living Mammals Are Giants That Live Up To 200 Years In The Icy Arctic
  • Entirely New Virus Detected In Bat Urine, And It’s Only The 4th Of Its Kind Ever Isolated
  • The First Ever Full Asteroid History: From Its Doomed Discovery To Collecting Its Meteorites
  • World’s Oldest Pachycephalosaur Fossil Pushes Back These Dinosaurs’ Emergence By 15 Million Years
  • The Hole In The Ozone Layer Is Healing And On Track For Full Recovery In The 21st Century, Thanks To Science
  • First Sweet Potato Genome Reveals They’re Hybrids With A Puzzling Past And 6 Sets Of Chromosomes
  • Why Is The Top Of Canada So Sparsely Populated? Meet The “Canadian Shield”
  • Humans Are In The Middle Of “A Great Evolutionary Transition”, New Paper Claims
  • Why Do Some Toilets Have Two Flush Buttons?
  • 130-Year-Old Butter Additive Discovered In Danish Basement Contains Bacteria From The 1890s
  • Prehistoric Humans Made Necklaces From Marine Mollusk Fossils 20,000 Years Ago
  • Zond 5: In 1968 Two Soviet Steppe Tortoises Beat Humans To Orbiting Around The Moon
  • Why Cats Adapted This Defense Mechanism From Snakes
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version